Research Article
Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer
Table 4
The sensitivity, specificity, and Youden’s index of the four markers individually and in combination.
| | Tumor markers | | Sensitivity (%) | | Specificity (%) | Youden’s index | | Adenocarcinoma | Squamous cell lung cancer | Small cell lung cancer | Lung cancer |
| | SCCA | 7.35 (5/68) | 50.00 (28/56) | 12.50 (1/8) | 25.76 (34/132) | 94.29 (132/140) | 0.20 | | NSE | 47.06 (32/68) | 50.00 (28/56) | 50.00 (4/8) | 48.48 (64/132) | 91.43 (128/140) | 0.40 | | CEA | 58.82 (40/68) | 35.71 (20/56) | 0.00 (0/8) | 45.45 (60/132) | 89.29 (125/140) | 0.35 | | CYFRA21-1 | 29.41 (20/68) | 71.43 (40/56) | 12.50 (1/8) | 46.21 (61/132) | 97.14 (136/140) | 0.43 | | SCCA + NSE | 47.06 (32/68) | 67.86 (38/56) | 62.50 (5/8) | 56.82 (75/132) | 91.43 (128/140) | 0.48 | | SCCA + CEA | 58.82 (40/68) | 69.64 (39/56) | 12.50 (1/8) | 60.61 (80/132) | 89.29 (125/140) | 0.50 | | SCCA + CYFRA21-1 | 29.41 (20/68) | 71.43 (40/56) | 25.00 (2/8) | 46.97 (62/132) | 90.71 (127/140) | 0.38 | | NSE + CEA | 66.18 (45/68) | 71.43 (40/56) | 50.00 (4/8) | 67.42 (89/132) | 89.29 (125/140) | 0.57 | | NSE + CYFRA21-1 | 52.94 (36/68) | 78.57 (44/56) | 62.50 (5/8) | 64.39 (85/132) | 88.57 (124/140) | 0.53 | | CEA + CYFRA21-1 | 58.82 (40/68) | 78.57 (44/56) | 12.50 (1/8) | 64.39 (85/132) | 89.29 (125/140) | 0.54 | | SCCA + NSE + CEA | 67.65 (46/68) | 75.00 (42/56) | 62.50 (5/8) | 70.45 (93/132) | 89.29 (125/140) | 0.60 | | SCCA + NSE + CYFRA21-1 | 52.94 (36/68) | 78.57 (44/56) | 75.00 (6/8) | 65.15 (86/132) | 88.57 (124/140) | 0.54 | | SCCA + CEA + CYFRA21-1 | 58.82 (40/68) | 91.07 (51/56) | 25.00 (2/8) | 70.45 (93/132) | 89.29 (125/140) | 0.60 | | NSE + CEA + CYFRA21-1 | 66.18 (45/68) | 89.29 (50/56) | 62.50 (5/8) | 75.76 (100/132) | 88.57 (124/140) | 0.64 | | SCCA + NSE + CEA + CYFRA21-1 | 67.65 (46/68) | 91.07 (51/56) | 75.00 (6/8) | 78.03 (103/132) | 85.00 (119/140) | 0.63 |
|
|
